#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4040	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2285	507.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1623	1623	C	561	C	509	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6350	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3954	479.7	0	.	n	.	0	T695C	SNP	695	695	T	1234	1234	C	488	C,A	434,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6350	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3954	479.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1876	1876	A	539	A,C	497,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6350	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3954	479.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2510	2510	C	597	C,T,A	534,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6350	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3954	479.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2584	2584	A	600	A	537	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6350	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3954	479.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3136	3136	C	540	C,T	481,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	544	folP	852	852	100.0	folP.l15.c4.ctg.1	1878	86.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1200	1202	AGC	116;115;115	A;G;C,A	95;98;95,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1118	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3734	89.6	1	SNP	p	S91F	0	.	.	271	273	TCC	727	729	TCC	103;103;103	T;C;C	94;96;96	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1118	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3734	89.6	1	SNP	p	D95N	0	.	.	283	285	GAC	739	741	GAC	100;100;100	G;A;C,A	96;96;94,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1118	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3734	89.6	1	SNP	p	D95G	0	.	.	283	285	GAC	739	741	GAC	100;100;100	G;A;C,A	96;96;94,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	M16I	NONSYN	46	48	ATG	620	622	ATT	95;95;95	A;T;T,G	75;76;70,2	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	D40A	NONSYN	118	120	GAC	692	694	GCC	79;79;79	G;C;C	68;68;70	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	704	706	CAC	78;76;76	C;A,G;C	70;70,1;71	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	I73M	NONSYN	217	219	ATC	791	793	ATG	66;66;66	A;T;G,C	63;64;64,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	A74S	NONSYN	220	222	GCG	794	796	TCG	66;66;66	T,G;C;G	63,1;63;65	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	Q75K	NONSYN	223	225	CAA	797	799	AAA	66;66;66	A,C;A;A	62,1;64;65	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	A77T	NONSYN	229	231	GCC	803	805	ACG	67;67;68	A;C;G	64;65;65	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	.	MULTIPLE	233	234	CA	807	809	AAA	68;68;67	A;A;A	66;65;64	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	D79N	NONSYN	235	237	GAT	812	814	AAT	68;68;68	A;A;T	64;62;65	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	G83Q	NONSYN	247	249	GGG	824	826	CAA	69;69;69	C,G;A,G;A,T	67,1;66,1;66,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	H90R	NONSYN	268	270	CAC	845	847	CGT	66;66;66	C;G,A;T,C	65;63,1;65,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	N110S	NONSYN	328	330	AAC	905	907	AGC	52;53;54	A;G;C	50;48;51	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	V143F	NONSYN	427	429	GTT	1004	1006	TTT	33;33;33	T;T;T	29;29;27	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	A154S	NONSYN	460	462	GCT	1037	1039	TCG	25;25;25	T;C;G	23;22;23	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	D155G	NONSYN	463	465	GAC	1040	1042	GGT	25;25;24	G;G;T	21;22;22	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	T161M	NONSYN	481	483	ACG	1058	1060	ATG	23;23;23	A;T;G	21;21;22	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	T169M	NONSYN	505	507	ACG	1082	1084	ATG	22;22;22	A;T;G	20;21;22	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	F178L	NONSYN	532	534	TTC	1109	1111	CTC	19;19;19	C;T;C	19;17;17	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	S183N	NONSYN	547	549	AGT	1124	1126	AAT	18;18;18	A;A;T	18;18;16	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	G195E	NONSYN	583	585	GGG	1160	1162	GAA	18;18;18	G;A;A	18;16;18	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	0	.	p	.	0	C206Q	NONSYN	616	618	TGC	1193	1195	CAG	16;16;16	C;A;G	16;16;16	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	188	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1364	41.1	1	SNP	p	G45D	0	.	.	133	135	GGC	707	709	GGC	76;76;76	G;G;C,T	67;68;71,1	mtrR.WHO_Z_01455:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1340	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3420	117.0	1	SNP	p	D86N	0	.	.	256	258	GAC	833	835	GAC	129;128;129	G;A;C	116;113;112	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1340	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3420	117.0	1	SNP	p	S87R	0	.	.	259	261	AGT	836	838	AGT	129;129;129	A;G;T	111;114;111	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1340	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3420	117.0	1	SNP	p	S87W	0	.	.	259	261	AGT	836	838	AGT	129;129;129	A;G;T	111;114;111	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1340	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3420	117.0	1	SNP	p	S87I	0	.	.	259	261	AGT	836	838	AGT	129;129;129	A;G;T	111;114;111	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1340	parC	2304	2304	100.0	parC.l6.c17.ctg.1	3420	117.0	1	SNP	p	S88P	0	.	.	262	264	TCC	839	841	TCC	129;129;125	T;C;C	113;114;113	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1094	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3290	99.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1881	1883	GGC	129;128;129	G;G;C	115;113;115	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1470	1472	GCA	134;134;134	G;C;A,G	120;121;126,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1473	1475	ATC	133;133;134	A;T;C	124;121;125	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1485	1487	GTG	133;132;132	G;T;G	119;120;119	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1485	1487	GTG	133;132;132	G;T;G	119;120;119	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1989	1991	ACC	126;126;127	A;C,A;C	113;107,1;115	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2043	2045	GCG	121;121;121	G;C;G	104;96;98	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2043	2045	GCG	121;121;121	G;C;G	104;96;98	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2166	2168	GGC	129;130;128	G,C;G,A,C;C,T	109,2;114,1,1;109,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2175	2177	GGC	131;131;130	G,C;G,T;C	106,4;112,1;111	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2814	103.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2193	2195	CCG	135;134;135	C,G;CG,CGG;G	110,1;104,1;106	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1376	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3610	114.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	578	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2422	71.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	843	843	C	82	C	72	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	130	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1561	23.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1287	1289	AAT	17;17;17	A;A;T	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	130	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1561	23.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1290	1292	AAT	17;17;17	A;A;T	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	130	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1561	23.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1314	1316	GCA	16;16;16	G;C;A	15;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	130	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1561	23.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1337	1339	GTA	14;14;14	G;T;A	13;12;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	130	porB1a	984	297	91.03	porB1a.l6.c30.ctg.1	1561	23.9	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1346	1346	A	13	A	13	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	0	.	p	.	0	I45V	NONSYN	133	135	ATT	610	612	GTT	189;189;189	G;T;T,G	164;167;170,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	0	.	p	.	0	I75V	NONSYN	223	225	ATT	700	702	GTT	183;182;183	G;T,C,G;T	174;165,1,1;174	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	0	.	p	.	0	S89T	NONSYN	265	267	AGC	742	744	ACC	201;202;202	A;C;C	185;187;186	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	0	.	p	.	0	I98V	NONSYN	292	294	ATC	769	771	GTC	197;197;198	G;T;C	176;173;174	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	1	SNP	p	G120K	1	.	.	358	360	AAG	835	837	AAG	198;198;200	A;A;G,T	175;175;174,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	1	SNP	p	A121N	1	.	.	361	363	AAC	838	840	AAC	199;197;197	A,C;A,C;C	169,1;172,1;172	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1796	129.6	1	SNP	p	N121D	0	.	.	361	363	AAC	838	840	AAC	199;197;197	A,C;A,C;C	169,1;172,1;172	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2580	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5394	143.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2259	2261	AAT	154;154;154	A;A;T,G	140;137;135,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	388	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1289	89.0	1	SNP	p	V57M	1	.	.	169	171	ATG	662	664	ATG	155;155;155	A;T,A;G	142;138,1;141	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
